CSIMarket
 
Pressure Biosciences Inc   (PBIO)
 

A surge in revenue fueled to reduce the deficit, at PBIO amid the fiscal period closing Dec 31 2021

PBIO recorded fourth quarter of 2021 operating shortfall of $-1.221148 million


Published Apr 23 2022
CSIMarket Team / CSIMarket.com


lab-217043__340 Strong Revenue growth in the fiscal period closing Dec 31 2021, by 91.375 % to $0.32 million fueled to cut losses to $-0.51 per share, from $-1.15 in same reporting season a year prior.

On the contrary to Q3 Revenue Tumbled by -39.194 % from $0.52 million and EPS improved from $-0.82 per share.


In the fiscal span closing December 31 2021 Pressure Biosciences Inc reported net deficit of $-3.880 million, instead of deficit of $-4.265 million in the same reporting season a year ago.

Additionally, the Pressure Biosciences Inc pointed out as well net loss of $-16.08 million and for the fiscal year 2022, revenue of $1.73 million.

Biotechnology & Pharmaceuticals Pressure Biosciences Inc has decreased it's deficit per share to $-1.61 from $-3.42 in the prior fiscal year, while Revenue deteriorated by -13.63 % from $2.00 million a year prior.

Pressure Biosciences Inc is expected to report next financial results on May 17, 2023.



Pressure Biosciences Inc's ROA

Pressure Biosciences Inc's ROA



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com